Emergent BioSolutions Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph C. Papa Jr.
- Full Time Employees
- 900
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 Professional Drive Gaithersburg MD United States of America 20879
- IPO Date
- Nov 15, 2006
- CIK
- 0001367644
- Website
- emergentbiosolutions.com
- Similar Companies
- Business
- Emergent BioSolutions Inc. (EBS) develops, manufactures and commercializes vaccines, therapeutics and medical countermeasures addressing public health threats including infectious diseases, opioid overdoses and biodefense risks; its core products encompass NARCAN Nasal Spray 4 mg (naloxone HCl, the first FDA-approved over-the-counter opioid overdose reversal agent), KLOXXADO Nasal Spray 8 mg (naloxone HCl), ACAM2000 (Smallpox (Vaccinia) Vaccine, Live, also indicated for mpox), BioThrax (Anthrax Vaccine Adsorbed), CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)), BAT (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – Equine), CNJ-016 (vaccinia immune globulin intravenous, human), raxibacumab (fully human monoclonal antibody for anthrax), Ebanga (ansuvimab-zykl for Ebola), and TEMBEXA (brincidofovir for smallpox; distributed pursuant to collaboration with Ridgeback Therapeutics). The company operates through three segments: Commercial Products (opioid reversal agents and related offerings), Medical Countermeasures (MCM) Products (anthrax, smallpox, botulism, Ebola and other biothreat solutions procured primarily by governments) and Services (contract development and manufacturing for biopharma partners). Founded in 1998 as BioPort Inc. through acquisition of Michigan Biologic Products Institute and renamed Emergent BioSolutions in 2004, it maintains headquarters in Gaithersburg, Maryland, with manufacturing facilities including sites in Baltimore, Maryland; Lansing, Michigan; and Bayview, Maryland; it serves civilian, military and government customers globally, with key markets in the United States, Canada and international public health agencies. Recent developments include an October 2025 investment agreement and strategic partnership with RocketVax Ltd. to lead U.S. manufacturing and commercialization of four next-generation vaccine candidates for infectious diseases, cancer and autoimmune disorders (one backed by a U.S. National Institutes of Health Project NextGen letter of intent); eleven U.S. government MCM contract modifications and product orders secured in 2025 totaling hundreds of millions of dollars for products including CYFENDUS, ACAM2000, VIGIV and BAT; a $65 million multi-year contract with the Ontario Ministry of Health for NARCAN Nasal Spray; approximately $550 million in additional MCM contract modifications; repayment of $168 million in debt and a new $250 million term loan to bolster financial position; completion of the $30 million sale of its Baltimore-Camden manufacturing site to Bora Pharmaceuticals in August 2024 as part of a multi-year transformation plan involving cost savings of $80 million annually through workforce reductions and facility closures; and divestiture of RSDL (Reactive Skin Decontaminant Lotion) to SERB Pharmaceuticals for $75 million in July 2024.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Emergent BioSolutions (EBS)
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)
Emergent Biosolutions Q2 Earnings Call Highlights
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Hantavirus cases spark surge in pharma and biotech stocks — here's why